2012/02/11

Bharangin, a diterpenoid quinonemethide, abolishes constitutive and inducible nuclear factor-κB (NF-κB) activation by modifying p65 on cysteine 38 residue and reducing inhibitor of nuclear factor-κB α kinase activation, leading to suppression of NF-κB-regulated gene expression and sensitization of tumor cells to chemotherapeutic agents.


Mol Pharmacol. 2011 Nov;80(5):769-81. Epub 2011 Jul 27.

Bharangin, a diterpenoid quinonemethide, abolishes constitutive and inducible nuclear factor-κB (NF-κB) activation by modifying p65 on cysteine 38 residue and reducing inhibitor of nuclear factor-κB α kinase activation, leading to suppression of NF-κB-regulated gene expression and sensitization of tumor cells to chemotherapeutic agents.

Gupta SC, Kannappan R, Kim J, Rahman GM, Francis SK, Raveendran R, Nair MS, Das J, Aggarwal BB.

Source

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX USA.


Fi.g 3B - PARP control blot is the same in left/right panels, flipped horizontally




Written by Time:

0 件のコメント:

コメントを投稿

登録: コメントの投稿 (Atom)